Pawlak D. – TechConnect Briefs

Dex40-GTMAC3, modified dextran as a novel heparin antagonist

Kalaska B., Kaminski K., Sokolowska E., Czaplicki D., Kujdowicz M., Stalinska K., Szczubialka K., Bereta J., Pawlak D., Nowakowska M., Mogielnicki A., Medical University of Bialystok, PL

Protamine is the only registered antidote preventing bleeding of patients treated with unfractionated heparin (UFH). However protamine may induce anaphylactic shock or serious hypotension. We aimed to develop an alternative fully synthetic UFH antidote as [...]

Nonclinical evaluation of heparin binding copolymer – HBC1 for restoring of blood coagulation after heparin treatment

Kalaska B., Sokolowska E., Kaminski K., Miklosz J., Shin-ichi Y., Błazejczyk A., Wietrzyk J., Kasacka I., Szczubialka K., Pawlak D., Nowakowska M., Mogielnicki A., Medical University of Bialystok, PL

The incredible progress and wide use of various medical devices during intravascular or cardiac interventions increased the need for administration of anticoagulants, such as heparins. Protamine sulfate – a protein isolated from salmons is the [...]